BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 24337769)

  • 1. A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer.
    Kang YK; Muro K; Ryu MH; Yasui H; Nishina T; Ryoo BY; Kamiya Y; Akinaga S; Boku N
    Invest New Drugs; 2014 Apr; 32(2):355-61. PubMed ID: 24337769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.
    Kyriakopoulos CE; Braden AM; Kolesar JM; Eickhoff JC; Bailey HH; Heideman J; Liu G; Wisinski KB
    Invest New Drugs; 2017 Jun; 35(3):290-297. PubMed ID: 28004284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
    Zhao S; Wu W; Jiang H; Ma L; Pan C; Jin C; Mo J; Wang L; Wang K
    Front Immunol; 2021; 12():731527. PubMed ID: 34804015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.
    Rimassa L; Assenat E; Peck-Radosavljevic M; Pracht M; Zagonel V; Mathurin P; Rota Caremoli E; Porta C; Daniele B; Bolondi L; Mazzaferro V; Harris W; Damjanov N; Pastorelli D; Reig M; Knox J; Negri F; Trojan J; López López C; Personeni N; Decaens T; Dupuy M; Sieghart W; Abbadessa G; Schwartz B; Lamar M; Goldberg T; Shuster D; Santoro A; Bruix J
    Lancet Oncol; 2018 May; 19(5):682-693. PubMed ID: 29625879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors.
    Rosen LS; Senzer N; Mekhail T; Ganapathi R; Chai F; Savage RE; Waghorne C; Abbadessa G; Schwartz B; Dreicer R
    Clin Cancer Res; 2011 Dec; 17(24):7754-64. PubMed ID: 21976535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial.
    Wagner AJ; Goldberg JM; Dubois SG; Choy E; Rosen L; Pappo A; Geller J; Judson I; Hogg D; Senzer N; Davis IJ; Chai F; Waghorne C; Schwartz B; Demetri GD
    Cancer; 2012 Dec; 118(23):5894-902. PubMed ID: 22605650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer.
    Tolaney SM; Tan S; Guo H; Barry W; Van Allen E; Wagle N; Brock J; Larrabee K; Paweletz C; Ivanova E; Janne P; Overmoyer B; Wright JJ; Shapiro GI; Winer EP; Krop IE
    Invest New Drugs; 2015 Oct; 33(5):1108-14. PubMed ID: 26123926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.
    Goldman JW; Laux I; Chai F; Savage RE; Ferrari D; Garmey EG; Just RG; Rosen LS
    Cancer; 2012 Dec; 118(23):5903-11. PubMed ID: 22605616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach.
    Pant S; Patel M; Kurkjian C; Hemphill B; Flores M; Thompson D; Bendell J
    Cancer Invest; 2017 Aug; 35(7):463-472. PubMed ID: 28662341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.
    Santoro A; Rimassa L; Borbath I; Daniele B; Salvagni S; Van Laethem JL; Van Vlierberghe H; Trojan J; Kolligs FT; Weiss A; Miles S; Gasbarrini A; Lencioni M; Cicalese L; Sherman M; Gridelli C; Buggisch P; Gerken G; Schmid RM; Boni C; Personeni N; Hassoun Z; Abbadessa G; Schwartz B; Von Roemeling R; Lamar ME; Chen Y; Porta C
    Lancet Oncol; 2013 Jan; 14(1):55-63. PubMed ID: 23182627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies.
    Yap TA; Olmos D; Brunetto AT; Tunariu N; Barriuso J; Riisnaes R; Pope L; Clark J; Futreal A; Germuska M; Collins D; deSouza NM; Leach MO; Savage RE; Waghorne C; Chai F; Garmey E; Schwartz B; Kaye SB; de Bono JS
    J Clin Oncol; 2011 Apr; 29(10):1271-9. PubMed ID: 21383285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).
    Yoshioka H; Azuma K; Yamamoto N; Takahashi T; Nishio M; Katakami N; Ahn MJ; Hirashima T; Maemondo M; Kim SW; Kurosaki M; Akinaga S; Park K; Tsai CM; Tamura T; Mitsudomi T; Nakagawa K
    Ann Oncol; 2015 Oct; 26(10):2066-72. PubMed ID: 26153496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.
    Baljevic M; Zaman S; Baladandayuthapani V; Lin YH; de Partovi CM; Berkova Z; Amini B; Thomas SK; Shah JJ; Weber DM; Fu M; Cleeland CS; Wang XS; Stellrecht CM; Davis RE; Gandhi V; Orlowski RZ
    Ann Hematol; 2017 Jun; 96(6):977-985. PubMed ID: 28337527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer.
    Yamamoto N; Murakami H; Hayashi H; Fujisaka Y; Hirashima T; Takeda K; Satouchi M; Miyoshi K; Akinaga S; Takahashi T; Nakagawa K
    Br J Cancer; 2013 Nov; 109(11):2803-9. PubMed ID: 24169346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors.
    Feldman DR; Einhorn LH; Quinn DI; Loriot Y; Joffe JK; Vaughn DJ; Fléchon A; Hajdenberg J; Halim AB; Zahir H; Motzer RJ
    Invest New Drugs; 2013 Aug; 31(4):1016-22. PubMed ID: 23417696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.
    Rimassa L; Bozzarelli S; Pietrantonio F; Cordio S; Lonardi S; Toppo L; Zaniboni A; Bordonaro R; Di Bartolomeo M; Tomasello G; Dadduzio V; Tronconi MC; Piombo C; Giordano L; Gloghini A; Di Tommaso L; Santoro A
    Clin Colorectal Cancer; 2019 Jun; 18(2):125-132.e2. PubMed ID: 30846365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tivantinib in hepatocellular carcinoma.
    Trojan J; Zeuzem S
    Expert Opin Investig Drugs; 2013 Jan; 22(1):141-7. PubMed ID: 23167786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma.
    Kudo M; Morimoto M; Moriguchi M; Izumi N; Takayama T; Yoshiji H; Hino K; Oikawa T; Chiba T; Motomura K; Kato J; Yasuchika K; Ido A; Sato T; Nakashima D; Ueshima K; Ikeda M; Okusaka T; Tamura K; Furuse J
    Cancer Sci; 2020 Oct; 111(10):3759-3769. PubMed ID: 32716114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).
    Monk P; Liu G; Stadler WM; Geyer S; Huang Y; Wright J; Villalona-Calero M; Wade J; Szmulewitz R; Gupta S; Mortazavi A; Dreicer R; Pili R; Dawson N; George S; Garcia JA
    Invest New Drugs; 2018 Oct; 36(5):919-926. PubMed ID: 30083962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors.
    Yamamoto N; Murakami H; Nishina T; Hirashima T; Sugio K; Muro K; Takahashi T; Naito T; Yasui H; Akinaga S; Koh Y; Boku N
    Ann Oncol; 2013 Jun; 24(6):1653-9. PubMed ID: 23413279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.